Assignment history

Inventors

• Robert D. Gordon - Veloxis Pharmaceuticals AS
• Per Holm - Veloxis Pharmaceuticals AS
• Anne-Marie Lademann - Veloxis Pharmaceuticals AS
• Tomas Norling - Veloxis Pharmaceuticals AS

All named inventors were likely employed by Veloxis Pharmaceuticals AS at the time of the patent application's filing, which is a common practice for corporate patent ownership.

Original assignee

The entity named as the original assignee on the issued patent is Veloxis Pharmaceuticals AS.

Veloxis Pharmaceuticals AS (now part of Veloxis Pharmaceuticals Inc.) developed and markets an extended-release tacrolimus formulation under the brand name Envarsus XR (known as LCP-Tacro in clinical development) for the improved treatment of transplant patients. This product embodies the claims of US 10864199.

Veloxis Pharmaceuticals AS was acquired by Asahi Kasei Pharma Corporation in 2020. Veloxis Pharmaceuticals Inc., the current assignee, continues to operate as a specialty pharmaceutical company focused on immunosuppressive treatments.

Assignment timeline

• 2016-02-11 (executed) / recorded N/A (implied)

  • Conveyance: Assignment (implied by initial application filing)
  • Assignor: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling (Inventors)
  • Assignee: Veloxis Pharmaceuticals A/S
  • Context: Initial assignment of patent rights from inventors to the corporate entity at the time of filing the patent application.

• 2018-02-15 (executed) / recorded 2018-02-15 — Reel 041170/0411

  • Conveyance: SECURITY INTEREST
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
  • Correspondent: COOLEY LLP, 1290 AVENUE OF THE AMERICAS, NEW YORK, NY 10104-3300.
  • Context: Securitization of assets, likely in conjunction with a loan or financing agreement using patents as collateral.

• 2020-01-23 (executed) / recorded 2020-01-23 — Reel 048743/0116

  • Conveyance: RELEASE BY SECURED PARTY
  • Assignor: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
  • Assignee: VELOXIS PHARMACEUTICALS A/S
  • Correspondent: COOLEY LLP, 1290 AVENUE OF THE AMERICAS, NEW YORK, NY 10104-3300. (This correspondent recurs in this chain.)
  • Context: Release of the security interest, returning unencumbered patent rights to Veloxis Pharmaceuticals A/S.

• 2021-03-17 (executed) / recorded 2021-03-17 — Reel 055740/0173

  • Conveyance: Assignment of Assignors Interest
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: VELOXIS PHARMACEUTICALS INC.
  • Correspondent: KUTAK ROCK LLP, 1650 ARCHER PARK DR, OMAHA, NE 68102.
  • Context: Corporate restructuring or transfer of US patent assets from the Danish parent company to its US subsidiary.

• 2021-04-02 (executed) / recorded 2021-04-02 — Reel 055800/0073

  • Conveyance: Assignment of Assignors Interest
  • Assignor: VELOXIS PHARMACEUTICALS A/S
  • Assignee: VELOXIS PHARMACEUTICALS INC.
  • Correspondent: KUTAK ROCK LLP, 1650 ARCHER PARK DR, OMAHA, NE 68102. (This correspondent recurs in this chain.)
  • Context: Supplemental or clarifying transfer of patent rights from the Danish parent to its US subsidiary.

• 2024-03-25 (executed) / recorded 2024-03-25 — Reel 062638/0048

  • Conveyance: Assignment of Assignors Interest
  • Assignor: LADEMANN, ANNE-MARIE; HOLM, PER; GORDON, ROBERT D
  • Assignee: LIFECYCLE PHARMA A/S
  • Correspondent: MCDERMOTT WILL & EMERY LLP, 1850 K STREET NW SUITE 1100, WASHINGTON, DC 20006.
  • Context: Assignment of individual inventor rights, potentially a corrective or clarifying action to perfect the chain of title.

• 2024-03-25 (executed) / recorded 2024-03-25 — Reel 062638/0049

  • Conveyance: Assignment of Assignors Interest
  • Assignor: NORLING, TOMAS
  • Assignee: LIFECYCLE PHARMA A/S
  • Correspondent: MCDERMOTT WILL & EMERY LLP, 1850 K STREET NW SUITE 1100, WASHINGTON, DC 20006. (This correspondent recurs in this chain.)
  • Context: Assignment of individual inventor rights, likely a concurrent corrective or clarifying action.

• 2024-03-25 (executed) / recorded 2024-03-25 — Reel 062638/0050

  • Conveyance: Assignment of Assignors Interest
  • Assignor: LIFECYCLE PHARMA A/S
  • Assignee: VELOXIS PHARMACEUTICALS A/S
  • Correspondent: MCDERMOTT WILL & EMERY LLP, 1850 K STREET NW SUITE 1100, WASHINGTON, DC 20006. (This correspondent recurs in this chain.)
  • Context: Transfer of the inventor-assigned rights from an intermediate entity (Lifecycle Pharma A/S, which was an earlier name for Veloxis's Danish parent) back to Veloxis Pharmaceuticals A/S, likely to ensure a complete and perfect chain of title for the ultimate owner, Veloxis Pharmaceuticals Inc.

Timeline diagram

timeline
    title Ownership of US 10864199
    2016 : Filed by Veloxis Pharma A/S
    2018 : Security interest to Athyrium LP
    2020 : Security interest released
    2020 : Veloxis Pharma A/S acquired
    2021 : Assigned to Veloxis Pharma Inc
    2024 : Inventors assign to Lifecycle Pharma A/S
         : Lifecycle Pharma A/S to Veloxis Pharma A/S

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. The assignees are either operating companies (Veloxis Pharmaceuticals AS/Inc.), an investment firm involved in a security interest (Athyrium), or an historical entity related to the operating company (Lifecycle Pharma A/S). There are no indications of licensing-only LLCs or registered-agent addresses without operations.
2. Known asserter in the chain — Not present. None of the assignees (Veloxis Pharmaceuticals AS/Inc., Athyrium Opportunities III Acquisition LP, Lifecycle Pharma A/S) are identified as known NPEs or high-frequency plaintiffs by public lists. Veloxis Pharmaceuticals Inc. is an operating company.
3. Repeat correspondent across the chain — Present. Cooley LLP appears as correspondent for the 2018-02-15 security interest and 2020-01-23 release (Reel 041170/0411, 048743/0116). Kutak Rock LLP appears for the 2021-03-17 and 2021-04-02 assignments (Reel 055740/0173, 055800/0073). McDermott Will & Emery LLP appears for all three 2024-03-25 assignments (Reel 062638/0048, 062638/0049, 062638/0050). While this indicates consistency within specific transactions, the firms are known full-service law firms, and the assignments are between related operating entities or a lender, not disparate shell entities.
4. Cascading transfers — Not present as an NPE pattern. The three assignments on 2024-03-25 (Reel 062638/0048, 062638/0049, 062638/0050) are consecutive, but they appear to be a coordinated effort to perfect title within the Veloxis corporate family, rather than a rapid transfer through unrelated shell entities for assertion purposes.
5. Pre-litigation transfer — Not present. The primary transfer to the current asserting entity, Veloxis Pharmaceuticals Inc., occurred in March/April 2021 (Reel 055740/0173, 055800/0073). The first infringement suit (1:22-cv-00909) was filed in 2022, well over 6 months after this transfer.
6. Bankruptcy fire-sale — Not present. There is no indication of bankruptcy proceedings for any entity in the chain. The 2018 security interest and 2020 release reflect financing activity, not a distress sale.
7. Privateering — Not present. Veloxis Pharmaceuticals Inc. is an operating company that directly manufactures and sells a product embodying the patent claims, and it is asserting the patent against generic competitors.
8. Defensive aggregator (anti-NPE) — Not present. The chain ends with Veloxis Pharmaceuticals Inc., an operating company. No defensive aggregators are involved.

Verdict

Operating-company assertion

The assignment timeline consistently shows ownership within the Veloxis Pharmaceuticals corporate family, with a temporary security interest from a legitimate investment firm. Veloxis Pharmaceuticals Inc. is an operating company that develops and markets a product (Envarsus XR) embodying the patent claims and is suing direct competitors (Accord Healthcare & Intas) over alleged infringement. The 2024 assignments appear to be corrective measures to perfect the chain of title rather than indicative of an NPE strategy.

USPTO Assignment Center search for US10864199.